Zobrazeno 1 - 10
of 200
pro vyhledávání: '"Azvudine"'
Autor:
Huaiya Xie, Yaqi Wang, Yan Xu, Luo Wang, Junping Fan, Siqi Pan, Chuan Shi, Xiaoyan Liu, Xiaoxing Gao, Xiaobei Guo, Siyuan Yu, Jia Liu, Dongming Zhang, Yanli Yang, Hong Zhang, Jinglan Wang, Aohua Wu, Xueqi Liu, Jihai Liu, Huadong Zhu, Xiang Zhou, Xinlun Tian, Mengzhao Wang
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract The study was to evaluate the clinical outcomes of azvudine versus nirmatrelvir-ritonavir against omicron strains of coronavirus disease 2019 infections and determine their comparative effectiveness. This retrospective study included 716 pat
Externí odkaz:
https://doaj.org/article/d88b3e55da7d4fe7873f45189db8222e
Publikováno v:
Infection and Drug Resistance, Vol Volume 17, Pp 4317-4325 (2024)
Siqin Zhang,1,* Songsong Tan,1,* Bin Yang,2 Yaoyao Wu,3 Guohang Yuan,3 Fengjiao Chen,4 Lin Liu3,5 1Department of Endocrinology and Metabolism, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, 550002, People’s Republic of China; 2De
Externí odkaz:
https://doaj.org/article/9160545218554d61a0bcff3d87ad48ea
Publikováno v:
Infection and Drug Resistance, Vol Volume 17, Pp 3967-3978 (2024)
Ximiao Yu,1,* Ruiqi Luo,2,* Guijuan Xie,2 Jiali Ji,3,4 Jiehong Wang,1 Xiyue Li,3 Xiaojun Qian,2 Xun Wang1,2,5 1Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu Province, People’s Republic of China; 2Department of Pulmonary and Cr
Externí odkaz:
https://doaj.org/article/d8e82d493dc54688b5b23018834f80fe
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 14, Iss 7, Pp 3140-3154 (2024)
Thymus is the important immune organ, responsible for T cell development and differentiation. The lower circulating T counts have been observed in patients who died from COVID-19 compared with survivors. Azvudine, also known as FNC, is a thymus-homin
Externí odkaz:
https://doaj.org/article/6dae7bb2a4a744aaba39f7163fa9d4a9
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 14 (2024)
BackgroundAzvudine, a repurposed oral small molecule antiviral drug, has potential effects in combating the SARS-CoV-2 virus. However, studies on its clinical efficacy in patients with COVID-19 are still limited and controversial, and further researc
Externí odkaz:
https://doaj.org/article/2ca0bba0526c41a2917078c0c43a63bf
Publikováno v:
The Clinical Respiratory Journal, Vol 18, Iss 7, Pp n/a-n/a (2024)
ABSTRACT Background Azvudine (FNC) is a novel small molecule antiviral drug for treating COVID‐19 that is available only on the Chinese market. Despite being recommended for treating COVID‐19 by the Chinese guidelines, its efficacy and safety are
Externí odkaz:
https://doaj.org/article/18d9409ec7434cb8a82cb3a8439c8253
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Numerous studies have explored the treatment outcomes of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19. However, direct comparisons between these two drugs are still relatively limited. This study aims to compare t
Externí odkaz:
https://doaj.org/article/43dd0f00925c4c0f8bb61455c65bf72c
Publikováno v:
Advanced Science, Vol 11, Iss 23, Pp n/a-n/a (2024)
Abstract COVID‐19 can lead to adverse outcomes in patients with pre‐existing diseases. Azvudine has been approved for treating COVID‐19 in China, but the real‐world data is limited. It is aimed to investigate the efficacy of Azvudine in patie
Externí odkaz:
https://doaj.org/article/ca6cfbe4500446c2ae2e83710d0fa8c7
Autor:
Yaqi Wang, Huaiya Xie, Luo Wang, Junping Fan, Ying Zhang, Siqi Pan, Wangji Zhou, Qiaoling Chen, Xueqi Liu, Aohua Wu, Hong Zhang, Jinglan Wang, Xinlun Tian
Publikováno v:
Virology Journal, Vol 21, Iss 1, Pp 1-9 (2024)
Abstract Background Azvudine has been approved for the treatment of coronavirus disease 2019 (COVID-19) patients in China, and this meta-analysis aims to illustrate the safety of azvudine and its effectiveness in reducing mortality. Methods PubMed, E
Externí odkaz:
https://doaj.org/article/159f3667cb2c492ab1c56ca2d8998e1e
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract This study aimed to explore the effectiveness and safety of azvudine, nirmatrelvir/ritonavir, and molnupiravir in adult patients with mild-to-moderate COVID-19. This retrospective cohort study included patients with mild-to-moderate COVID-19
Externí odkaz:
https://doaj.org/article/0609dcd3211e449d9c11f02e5d41bec0